Authors
Latest:
A Match Made in ClinicHow artificial intelligence, wearable devices, and translational informatics are changing healthcare.
Latest:
A Match Made in ClinicHow artificial intelligence, wearable devices, and translational informatics are changing healthcare.
Latest:
5 Ways to Shape a Regulatory Affairs Workforce for the FuturePharmaceutical regulatory divisions should use the same discipline, rigor and focus on the talent pipeline as they do the product pipeline, writes Karin Van Baelen.
Latest:
Measuring the Probability of Pricing and Access SuccessThere is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
Measuring the Probability of Pricing and Access SuccessThere is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.
Latest:
Measuring the Probability of Pricing and Access SuccessThere is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.
Latest:
Is Patient Engagement Brexit-Ready?Whatever the final outcome of Brexit, investing in supporting advocacy communities will be an important element of maintaining trusted relationships with patient groups and stakeholders in the UK and the EU, write Nick Hicks and Tamsin Rose.
Latest:
Three Key Dynamics to Understand for Canadian Market AccessThis article discusses three key considerations a manufacturer should either understand or seek a consulting partner to guide them through a commercialization plan.
Latest:
The Biopharma-Led Platform Business Model in HealthcareWhat we can learn from an early leader?
Latest:
Why Pharma Should Pay Attention to Copay Accumulator ProgramsAn understanding of copay accumulator and maximizer benefit design programs.
Latest:
Key Observations on GDPRAs we pass the 6-month anniversary of theGeneral Data Protection Regulation's effective date, the number of organizations which boast 100% GDPR compliance has certainly increased. But life sciences companies are still grappling with implementation of the policy and procedure changes, writes Ashley Williams.
Latest:
Identity Crisis: Data Protection Roles for Life Sciences CompaniesJames Clark addresses one of the key questions data protection and compliance officers are asking following the implementation of the General Data Protection Regulation -"What role am I playing under the GDPR?"
Latest:
Finding the Right Digital Health PartnerPharma companies are increasingly expanding their portfolios into digital health solutions. To find the right partners, there are several key considerations that inform their evaluation and selection.
Latest:
Digital patient solutions: the secret to delivering and securing adoptionIndustry experts cover how to develop digital patient solutions that address real unmet needs and secure adoption.
Latest:
Confronting a Challenging Macroeconomic Environment with InnovationWebinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT
Latest:
5 Myths About BiosimilarsThe introduction of biosimilars has been one of the biggest milestones in autoimmune treatment, but an air of uncertainty still lingers around the true impact of these new players. So what has happened in the market since their arrival?
Latest:
Fuel Growth Through Innovative Talent StrategiesJohn Ebeid outlines talent strategies to reduce an organization's labor costs and increase quality.
Latest:
Global Health: The Need for ConsensusYou can’t make progress without consensus. This holds true for Brexit and for the unparalleled opportunity that the WHO Roadmap report on Access to Medicines and Vaccines presents, writes IFPMA's Greg Perry.
Latest:
Precision Financing of Durable, Potentially Curative TherapiesWhile gene therapies and cellular treatments are a boon for patients, they can be a financial bane for payers. Jane Barlow, Russell Teagarden, and Mark Trusheim outline alternative financing approaches, customizable for each payer’s needs and for each therapy’s characteristics.
Latest:
Engaging with Oncology Providers in a Virtual World*** Live: Thursday, Oct. 29, 2020 at 2pm EDT | 1pm CDT | 11am PDT*** E Get a behind the scenes look into the community oncology provider world through the COVID-19 emergence. Understand provider education needs and preferences and formulate effective strategies to deliver education most adapted to their needs in a virtual world. ***On demand available after final airing until Oct. 29, 2021***
Latest:
When to Utilize Commercial OutsourcingWhen deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.
Latest:
Op-Ed: Opening the Golden DoorThe talent and tenacity of immigrants can help drive the life sciences industry into the future, if we have the will and the wisdom to encourage it.
Latest:
From PI to Payer to Patient: RWE From the Perspective of Each Key StakeholderHow real-world evidence creates shared value for stakeholders across the healthcare spectrum.
